← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Basal Cell Carcinoma

MONDO:0005341 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 59 citations openscientist · 70 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Basal cell carcinoma is driven in nearly all cases by constitutive activation of the Hedgehog (HH) signaling pathway — most often loss-of-function mutation of the SMO repressor PTCH1 or activating mutation of SMO — leading to downstream GLI transcription-factor activation and basal keratinocyte proliferation.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 95% loss of PTCH-mediated repression of SMO → activation of GLI transcriptional programs → keratinocyte proliferation and tumor growth
Falcon lays out the same causal chain (PTCH derepression of SMO → GLI transcription → proliferation).
DOI:10.3390/ijms25137056, DOI:10.3390/cells12212534
openscientist CONCORDANT 97% Basal cell carcinoma (BCC) is driven in nearly all cases by mutations that constitutively activate upstream Hedgehog (HH) signaling, either through loss-of-function mutations in PTCH1 or gain-of-function mutations in SMO
OpenScientist states the HH-driver mechanism verbatim, naming PTCH1 LOF and SMO GOF as the two routes to constitutive activation.
PMID:41240053

The large majority of sporadic BCCs (~85%) carry Hedgehog-pathway mutations, with PTCH1 loss-of-function in roughly 73% and activating SMO mutations in about 10-20% of cases.

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% ~85% of sporadic BCCs carry Hedgehog-pathway mutations
Falcon gives the aggregate ~85% HH-pathway mutation burden and elsewhere breaks it into PTCH ~73% LOF and SMO ~20% GOF.
DOI:10.3390/cells12212534
openscientist CONCORDANT 90% Loss-of-function mutations in the Hedgehog receptor PTCH1 are found in ~73% of sporadic BCCs
OpenScientist reports the same PTCH1 ~73% frequency and SMO ~10-20% in its causal-gene table.
PMID:41884741

Chronic ultraviolet radiation is the dominant environmental driver of BCC, inducing UV-signature DNA damage (and epigenetic dysregulation) on a background of genetic susceptibility.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% is consistently highlighted as a principal causal factor, with additional contributions from ionizing radiation and genetic predisposition
Falcon identifies UV radiation as the principal causal factor with ionizing radiation and genetic predisposition as contributors.
DOI:10.6004/jnccn.2023.0056, DOI:10.3390/cells12212534
openscientist CONCORDANT 90% Chronic ultraviolet radiation (UVR), the dominant risk factor, induces DNA damage and inflammation that dysregulate epigenetic enzymes (e.g., DNMTs, HDACs)
OpenScientist calls UVR the dominant risk factor and adds the epigenetic (DNMT/HDAC) dysregulation arm.
PMID:42074595

BCC is the most common human malignancy (~80% of keratinocyte cancers) and behaves as an indolent, locally invasive tumor with a very low rate of metastasis.

UNANIMOUS INTEGRATED
epidemiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Basal cell carcinoma (BCC) is the most common skin cancer and typically behaves as an indolent, locally invasive tumor with very low metastatic potential
Falcon frames BCC as the most common skin cancer, indolent and locally invasive with very low metastatic potential (<0.1%).
DOI:10.6004/jnccn.2023.0056, DOI:10.1111/ddg.15566
openscientist CONCORDANT 90% Basal cell carcinomas (BCC) are the most common, comprising 80% of keratinocyte cancers, but have a very low rate of metastases and low mortality
OpenScientist quantifies BCC as ~80% of keratinocyte cancers with a very low metastatic rate and low mortality.
PMID:31585338

Gorlin (basal cell nevus) syndrome — autosomal dominant germline mutation of PTCH1, SUFU, SMO, or PTCH2 — provides the hereditary proof that HH-pathway lesions cause BCC, producing multiple early-onset BCCs.

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 80% Gorlin syndrome/NBCCS is linked to germline PTCH1; a 2023 review reports a small fraction of BCC is linked to Gorlin syndrome
Falcon notes germline PTCH1 in Gorlin/NBCCS as the syndromic predisposition but names only PTCH1.
DOI:10.3390/cells12212534
openscientist CONCORDANT 90% It occurs due to a defective hedgehog cell signaling pathway, caused by heterozygous germ-line mutations in either Patched 1 (PTCH1), Suppressor of fused (SUFU), Smoothened (SMO), or Patched 2 (PTCH2) genes, leading to tumorigenesis and various developmental anomalies
OpenScientist gives the full four-gene germline spectrum (PTCH1/SUFU/SMO/ PTCH2) for Gorlin syndrome.
PMID:41884741

BCC arises from epidermal keratinocyte lineages, with lineage-tracing evidence implicating interfollicular epidermis for superficial BCC and hair follicle stem cells for nodular BCC.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% lineage evidence indicates superficial BCC may arise from interfollicular epidermis, nodular BCC from hair follicle stem cells
Falcon maps the two cells of origin to the two clinical subtypes explicitly.
DOI:10.3390/ijms25158452
openscientist CONCORDANT 80% Lineage-tracing studies show that BCC-initiating cells are reprogrammed to hair follicle progenitor-like fate
OpenScientist agrees on the follicular/interfollicular origins and adds the hair-follicle-progenitor reprogramming detail.
PMID:23196843, PMID:28070642

Treatment is tiered: surgical excision including Mohs micrographic surgery is standard for localized disease, Hedgehog pathway inhibitors are first-line systemic therapy for advanced BCC, and anti-PD-1 cemiplimab provides durable responses after HH-inhibitor failure or intolerance.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Locally advanced or metastatic BCC after HHI intolerance/progression; second-line systemic
Falcon places cemiplimab as second-line systemic therapy after HH-inhibitor progression/intolerance, with surgery/Mohs and HHIs upstream.
DOI:10.1016/S1470-2045(21)00126-1, DOI:10.5826/dpc.1304a252
openscientist CONCORDANT 95% Updated evidence confirms Hedgehog pathway inhibitors (HHIs) as the standard first-line therapy for advanced BCC, while programmed death-1 (PD-1) blockade with cemiplimab has established durable responses after HHI failure
OpenScientist states the HHI-first, cemiplimab-after-failure sequence verbatim.
PMID:41703999

First-line Hedgehog pathway inhibitors (vismodegib, sonidegib) achieve high objective response rates in advanced BCC (approximately 65-89%).

MAJORITY INTEGRATED
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Sonidegib showed superior real-world efficacy compared to pivotal trial data (ORR 89% vs. 60.6%)
OpenScientist quantifies HHI response rates (vismodegib 65%, sonidegib up to 89% real-world).
PMID:40834113, PMID:41703999
falcon PARTIAL 40% Guideline-supported first-line systemic option for advanced BCC
Falcon identifies vismodegib/sonidegib as guideline-supported first-line systemic therapy but explicitly did not extract HHI objective response rates from its retrieved sources — coverage without the efficacy magnitude.
DOI:10.3390/ijms25137056, DOI:10.1111/ddg.15566

Oral nicotinamide has been proposed as BCC chemoprevention, but the pooled evidence for a significant BCC-specific reduction is mixed.

SINGLE LEAD
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 60% when combining immunocompetent and immunosuppressed cohorts; authors conclude insufficient evidence for significant reduction
Falcon reviews the nicotinamide chemoprevention literature and reports the mixed/non-significant pooled BCC result (Tosti 2023 vs Mainville 2022).
DOI:10.3390/nu16010100, DOI:10.1177/12034754221078201
openscientist SILENT —
OpenScientist does not address oral nicotinamide chemoprevention (its prevention section centers on UV avoidance, sunscreen, and topical photolyase).
Left as a research lead rather than promoted: the chemoprevention evidence is mixed and partly oriented toward broader non-melanoma skin cancer prevention.

Narrative

Overview

Both providers frame basal cell carcinoma as the most common human malignancy — an indolent, locally invasive keratinocyte cancer driven in nearly all cases by constitutive Hedgehog pathway activation (PTCH1 loss-of-function or SMO gain-of-function → GLI transcription), triggered by chronic UV exposure on a background of genetic susceptibility, and managed by a tiered ladder from surgery to Hedgehog inhibitors to PD-1 blockade.

Agreement

Both identify Hedgehog pathway activation as the central mechanism, usually through PTCH1 loss of function or SMO activation followed by GLI transcriptional activation and basal-cell proliferation, and agree on the ~73% PTCH1 / ~10-20% SMO mutation frequencies. They agree UV radiation is the dominant environmental driver, that Gorlin syndrome is the hereditary proof-of-concept, that BCC is very rarely metastatic, and on the core therapeutic categories: excision/Mohs for localized disease, Hedgehog pathway inhibitors for locally advanced or metastatic disease, and cemiplimab (PD-1 blockade) after Hedgehog inhibitor failure.

Divergence

Falcon emphasized guideline-facing clinical management: recurrence benchmarks, NCCN-style treatment placement, and systemic photoprotection / nicotinamide chemoprevention — but explicitly declined to extract HH-inhibitor objective response rates or a consistent epigenetic signature from its sources. OpenScientist was broader and more quantitative on efficacy (vismodegib ORR 65%, sonidegib up to 89%) and added pathway context (Wnt/beta-catenin, TP53, PI3K/AKT/mTOR), the immune microenvironment, epigenomic reprogramming, dermoscopy/RCM/AI-assisted diagnosis, and animal-model detail. The differences are coverage and quantification, not direct contradictions.

Integration

The core PTCH1/SMO/Hedgehog/GLI cascade, UV etiology, subtype phenotypes, Gorlin-syndrome germline genetics, cell-of-origin lineages, and the surgery/HHI/cemiplimab treatment ladder are all supported by both providers and align with kb/disorders/Basal_Cell_Carcinoma.yaml; the HH-inhibitor response-rate quantification is contributed mainly by OpenScientist.

Not integrated (leads)

Nicotinamide chemoprevention was retained as a research lead rather than promoted, because the cited evidence is mixed and partly oriented toward broader non-melanoma skin cancer prevention. Detailed dermoscopy patterns, AI diagnostic tooling, and model-organism variants were likewise left in research provenance.

Cross-provider synthesis comparing two independent reports: falcon (guideline/management-focused) and openscientist (comprehensive, 15-domain). No direct contradictions were found; divergence is coverage and quantification (OpenScientist quantifies HH-inhibitor response rates and epigenetic reprogramming that Falcon covers only qualitatively or declines to assert; Falcon covers nicotinamide chemoprevention that OpenScientist omits). All best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets were intentionally left to the main curation pipeline pending fetch-reference verification.